106 related articles for article (PubMed ID: 15546561)
1. Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro.
McFadden DW; Riggs DR; Jackson BJ; Vona-Davis L
Am J Surg; 2004 Nov; 188(5):516-9. PubMed ID: 15546561
[TBL] [Abstract][Full Text] [Related]
2. Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms.
McFadden DW; Riggs DR; Jackson BJ; Cunningham C
Oncol Rep; 2008 Feb; 19(2):563-6. PubMed ID: 18202808
[TBL] [Abstract][Full Text] [Related]
3. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
[TBL] [Abstract][Full Text] [Related]
5. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
[TBL] [Abstract][Full Text] [Related]
6. RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells.
Torquati A; O'rear L; Longobardi L; Spagnoli A; Richards WO; Daniel Beauchamp R
Surgery; 2004 Aug; 136(2):310-6. PubMed ID: 15300196
[TBL] [Abstract][Full Text] [Related]
7. MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Vona-Davis L; Frankenberry K; Cunningham C; Riggs DR; Jackson BJ; Szwerc MF; McFadden DW
J Surg Res; 2005 Jul; 127(1):53-8. PubMed ID: 15964304
[TBL] [Abstract][Full Text] [Related]
8. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.
Hughes SJ; Nambu Y; Soldes OS; Hamstra D; Rehemtulla A; Iannettoni MD; Orringer MB; Beer DG
Cancer Res; 1997 Dec; 57(24):5571-8. PubMed ID: 9407969
[TBL] [Abstract][Full Text] [Related]
9. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line.
Jaiswal K; Lopez-Guzman C; Souza RF; Spechler SJ; Sarosi GA
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G335-42. PubMed ID: 16239404
[TBL] [Abstract][Full Text] [Related]
10. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
11. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Ogunwobi OO; Beales IL
Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146
[TBL] [Abstract][Full Text] [Related]
12. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus.
Piazuelo E; Jiménez P; Strunk M; Santander S; García A; Esteva F; Lanas A
Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):150-61. PubMed ID: 17085323
[TBL] [Abstract][Full Text] [Related]
14. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
[TBL] [Abstract][Full Text] [Related]
15. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma.
McFadden DW; Riggs DR; Jackson BJ; Vona-Davis L
Am J Surg; 2003 Nov; 186(5):552-5. PubMed ID: 14599624
[TBL] [Abstract][Full Text] [Related]
16. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Keswani RN; Chumsangsri A; Mustafi R; Delgado J; Cohen EE; Bissonnette M
Dis Esophagus; 2008; 21(6):514-21. PubMed ID: 18840136
[TBL] [Abstract][Full Text] [Related]
18. Barrett's esophagus-is it bad for your health?
Falk GW
Am J Gastroenterol; 2005 Dec; 100(12):2622-3. PubMed ID: 16393210
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
20. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
